Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study
Authors:
Open Access
- 18 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (1) , ofaa562
Abstract
High-quality evidence confirms that the clinical efficacy of peramivir in severe influenza patients with primary viral pneumonia is lacking. To optimize clinical medication, we evaluate the different efficacy between peramivir and oseltamivir in the treatment of severe influenza A with primary viral pneumonia. A single-center, randomized, controlled trial was conducted during the Chinese influenza season from December 2018 to April 2019 in patients with severe influenza A with primary viral pneumonia. A total of 40 inpatients were enrolled and treated with either intravenous peramivir (300 mg, once daily for 5 days) or oral oseltamivir (75 mg, twice daily for 5 days). The duration of influenza virus nucleic acid positivity in the oseltamivir group and the peramivir group was 2.95 days and 2.80 days, respectively. The remission times of clinical symptoms in the oseltamivir group and the peramivir group were 3.90 days and 3.25 days, respectively. In addition, the remission time of cough symptoms in the peramivir group (63.89 hours) was shorter than that in the oseltamivir group (75.53 hours). There was no significant difference between these values (P > .05). The remission time of fever symptoms in the oseltamivir group was 23.67 hours, which was significantly longer than that in the peramivir group (12.32 hours) (P = .034). Peramivir is no less effective than oseltamivir in the treatment of severe influenza A with primary viral pneumonia, and patients treated with peramivir had significantly shorter remission times of fever symptoms than those treated with oseltamivir.Keywords
Funding Information
- Science and Technology Information Network (Z2018188)
This publication has 23 references indexed in Scilit:
- Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza InfectionsFrontiers in Microbiology, 2016
- Peramivir: an intravenous neuraminidase inhibitorExpert Opinion on Pharmacotherapy, 2015
- The Effect of Intravenous Peramivir, Compared with Oral Oseltamivir, on the Outcome of Post-Influenza Pneumococcal Pneumonia in MiceAntiviral Therapy, 2015
- Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): A drug use investigationJournal of Infection and Chemotherapy, 2014
- Efficacy and Safety of Clearing Heat and Detoxifying Injection in the Treatment of Influenza: A Randomized, Double‐Blinded, Placebo‐Controlled TrialEvidence-Based Complementary and Alternative Medicine, 2014
- Phase III Randomized, Double-Blind Study Comparing Single-Dose Intravenous Peramivir with Oral Oseltamivir in Patients with Seasonal Influenza Virus InfectionAntimicrobial Agents and Chemotherapy, 2011
- Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in miceAntiviral Research, 2008
- Antiviral agents active against influenza A virusesNature Reviews Drug Discovery, 2006
- Anti-influenza virus activity of peramivir in mice with single intramuscular injectionAntiviral Research, 2006
- InfluenzaThe Lancet, 1999